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Abstract
Purpose—Patient-reported outcomes (PROs) have been found to be significant predictors of
clinical outcomes such as overall survival (OS), but the effect of demographic and clinical factors
on the prognostic ability of PROs is less understood. Several PROs derived from the 12-item Short
Form Health Survey (SF-12) and M. D. Anderson Symptom Inventory (MDASI) were
investigated for association with OS, with adjustments for other factors, including performance
status.
Methods—A retrospective analysis was performed on data from 90 patients with stage IV non-
small cell lung cancer. Several baseline PROs were added to a base Cox proportional hazards
model to examine the marginal significance and improvement in model fit attributable to the PRO:
mean MDASI symptom interference level; mean MDASI symptom severity level for five selected
symptoms; SF-12 physical and mental component summaries; and the SF-12 general health item.
Bootstrap resampling was used to assess the robustness of the findings.
Results—The MDASI mean interference level had a significant effect on OS (p = 0.007) when
the model was not adjusted for interactions with other prognostic factors. Further exploration
suggested the significance was due to an interaction with performance status (p = 0.001). The
MDASI mean symptom severity level and the SF-12 physical component summary, mental
component summary, and general health item did not have a significant effect on OS.
Conclusions—Symptom interference adds prognostic information for OS in advanced lung
cancer patients with poor performance status, even when demographic and clinical prognostic
factors are accounted for.
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Introduction
The use of patient-reported outcomes (PROs) in oncology has increased steadily in the past
decade. With the emergence of the Patient-Reported Outcomes Measurement System [1],
the publication of the U.S. Food and Drug Administration’s guidance to support labeling
claims [2], and the development of the PRO version of the Common Terminology Criteria
for Adverse Events [3], we expect to see continued use of PROs in descriptive studies and
clinical trials. This use is being facilitated by the accumulation of validation evidence for
widely used assessment tools such as the M. D. Anderson Symptom Inventory (MDASI) [4],
the Functional Assessment of Chronic Illness Therapy [5], the European Organisation for
Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 [6, 7],
and the 36-item Short-Form Health Survey (SF-36) [8] or its derivative, the SF-12 [9].
PROs do not only capture symptom or quality-of-life information for clinical use, they also
often serve as prognostic factors for clinical outcomes such as overall survival [10–12].
Indeed, some studies have suggested that patient-reported quality-of-life information is a
more valuable prognostic factor than clinician-assessed performance status [10]. However,
most studies have found only modest improvement in predictive ability when PROs are
added to models already containing other prognostic factors [10, 13]. Many PROs,
especially those pertaining to the interference of symptoms with patients’ daily activities,
have not been studied as predictors of survival.
In this study, we sought to test whether adding various PROs to models containing
established prognostic factors would improve the prediction of survival in patients with
advanced non-small cell lung cancer (NSCLC). We placed particular emphasis on a less-
studied PRO: baseline ratings of the interference scale of the MDASI, which measures how
much symptoms interfere with life domains. Although symptom interference was shown
previously to be predictive of primary tumor recurrence in patients with brain tumors [14],
symptom interference has not been used to examine survival in patients with lung cancer.
We also considered the added prognostic ability of several other PROs derived from either
the MDASI or the SF-12. Because many studies modeling survival have used performance
status as part of a statistically significant index (e.g., [15–19], we were particularly
interested in whether PROs improved survival prediction when models were adjusted for the
“gold standard” of performance status.
Methods
Patients
Patients were recruited between January 2004 and December 2008 from the thoracic
medical oncology clinic at The University of Texas MD Anderson Cancer Center. Eligible
patients had stage IV NSCLC, were at least 18 years old, spoke English, had an Eastern
Cooperative Oncology Group performance status (ECOG PS) of 0, 1, 2, or 3, and were
scheduled for first-line chemotherapy. Patients provided written informed consent, and the
MD Anderson Institutional Review Board approved the study.
The current study is a reanalysis of data obtained in a previous study [20], for which patients
were recruited from several kinds of treatment facility, including MD Anderson. Because of
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variations in symptom management between tertiary cancer centers and other hospitals,
patients were excluded from the present study if they were not treated at MD Anderson.
Prognostic factors
With the goal of understanding the added benefit of various PROs in modeling overall
survival, we considered prognostic factors of two types: those based on baseline
demographic or clinical variables related to overall survival according to previous studies
[11, 12, 14], and those based on baseline PROs. The demographic and clinical prognostic
factors were age (in years), ECOG PS (poor, defined as ≥ 2, vs. good, defined as ≤ 1);
previous chemotherapy (yes vs. no); and sex (male vs. female).
The PROs considered were derived from the baseline administration of the MDASI [4] and
the SF-12 [9]. The MDASI solicits patient self-report of the severity of 13 common cancer-
related symptoms and the degree to which symptoms interfere with daily functioning [4].
The severity of each symptom is reported on an integer scale of 0 (“not present”) to 10 (“as
bad as you can imagine”). For this study, we used the MDASI-LC [21], a validated lung
cancer version of the MDASI that assesses three additional symptoms, constipation,
coughing, and sore throat. The six MDASI symptom interference items also are reported
using an integer scale of 0 (“did not interfere”) to 10 (“interfered completely”). These items
measure interference with activity, work, walking, mood, relations with others, and
enjoyment of life.
The mean of all symptom severity scores can provide a convenient one-number summary for
use as a prognostic factor; however, to have a more sensitive measure we elected to use the
mean of only five of 15 MDASI symptom scores (the MDASI-LC item “sore throat” was
excluded from the analysis because it is related to radiation therapy, which none of our
sample received). In a previous report of data from a sample that included patients in the
present study, symptoms were ranked by severity and analyzed as predictors of overall
survival on an individual basis [12]; in the current study, we calculated the composite score
of the five symptoms with the highest average baseline levels (fatigue, disturbed sleep,
shortness of breath, drowsiness, and pain), rather than analyzing them individually.
Mendoza et al (2011) suggested that different composite scores can be derived using various
combinations of MDASI-LC items as long as they are specified a priori. We also evaluated
the mean of the scores for the six interference items as a potential prognostic factor.
The SF-12 is a validated derivative of the SF-36 [8, 9]. The 12 items of the SF-12 include
one item for the respondent’s self-reported general health. One apparent advantage of a
single-item measure is its simplicity [22]. The five response categories for the general health
item were combined to form a binary response: poor or fair vs. excellent, very good, or
good. The SF-12 items can be combined to form the physical component summary (PCS)
and mental component summary (MCS) [9], each of which ranges from 0 (worst) to 100
(best). In addition to the dichotomized general health item, we evaluated the PCS and MCS
as potential prognostic factors.
Statistical analysis
Descriptive statistics for the prognostic factors and PROs were computed. In addition, the
univariate significance of each potential prognostic factor in a Cox proportional hazards
model was assessed. To facilitate comparisons, only data from patients with observed values
for each factor considered were included. This guaranteed that the same subset of patients
was used in every analysis.
Most of the factors evaluated in this study were categorical, but several were treated as
quantitative factors. Age, SF-12 PCS, and SF-12 MCS were manifestly quantitative.
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Although both the mean MDASI interference level and the mean MDASI symptom severity
level were based on ordinal items rather than quantitative measurements, the 11 possible
categories for each item were sufficiently refined and had an inherent equal spacing to
justify their treatment as a quantitative response; this assumption was even more reasonable
for the average of several such items.
To assess the added prognostic ability of the various PROs considered, a Cox proportional
hazards model was fit using the demographic and clinical factors noted above. This base
model was assessed for validity. To this base model was added in turn each of the PROs,
and if the PRO significantly improved the model fit (likelihood ratio test p ≤ 0.05), then
interactions between the PRO and other factors were also considered.
The additive benefit of a potential prognostic factor to a model can be assessed by
comparing the C statistic for models with and without the factor. The C statistic [23]
measures the concordance between the model’s predicted risk and overall survival for all
pairs of patients in which it is possible to determine which patient lived longer [24].
Bootstrapping techniques were used to check the robustness of the findings. This was
particularly important because of the relatively small ratio of events to factors in the models.
The small ratio heightened concerns about the potential of influential points to drive model
conclusions. The bootstrap procedure implemented was to construct confidence intervals for
hazard ratios (HRs) using the percentile method. The preliminary step was to resample (with
replacement) the same number of observations from the original data set 1,000 times and
then to refit a given model to each of these resampled data sets. The HR estimate for any
factor of interest was computed for each sample, and the 2.5th and 97.5th percentiles of
these HR estimates from the 1,000 samples were used to form a 95% bootstrap confidence
interval. This is one of the most straightforward bootstrap techniques that can be used [25].
In addition, we determined the proportion of the bootstrap samples for which the factor had
p ≤ 0.05. Such a proportion can be used in assessing the usefulness of a prognostic factor
[26].
All calculations were performed using R [27] with the survival package [28]. P-values are in
all instances based on the (two-sided) likelihood ratio test.
Results
Of a potential pool of 95 patients, 90 had no missing information for any of the factors and
thus were included in our analysis. The five patients with missing information had missing
SF-12 PCS and SF-12 MCS scores (three patients), ECOG PS (one patient), MDASI pain
severity (one patient), and MDASI relationship interference (one of the patients also missing
SF-12 PCS and SF-12 MCS). The median time span between diagnosis of lung cancer and
baseline symptom assessment was 58 days. At the time of the initial analysis, 88 of the 90
patients had died. The median survival time was 8.4 months.
Summary information for these 90 patients, including the univariate significance of each
potential prognostic factor, is included in Table 1. For the factors treated as quantitative, the
comparison for the HRs corresponds to a change in the measure of roughly one-half
standard deviation. Using an unadjusted α of 0.05 for each factor as a predictor of overall
survival, only the mean MDASI symptom interference score and the SF-12 general health
item were found to be significant. The Cronbach alpha for the composite of the five
symptoms with the highest average baseline levels (fatigue, disturbed sleep, shortness of
breath, drowsiness and pain) was 0.74. The mean score from these five symptoms for
patients with good ECOG PS was 1.9 (SD=1.49), whereas patients with poor ECOG PS had
Barney et al. Page 4
Qual Life Res. Author manuscript; available in PMC 2014 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
a mean score of 3.19 (SD=1.75). Hence, the groups differed statistically (p<.001) and
meaningfully (effect size = 0.79), demonstrating known-group validity.
The base Cox model with sex, age, previous chemotherapy, and ECOG PS had a
pronounced weakness because the estimated survival function appeared to behave
differently for good ECOG PS than for poor ECOG PS. Because of this, we stratified the
base Cox model by good vs. poor ECOG PS. Figure 1 depicts the estimated survival curve
for patients [29] in each stratum.
Table 2 displays the estimated adjusted HR of each factor for this base model and for the
models with each PRO-derived measure added. Each PRO had its estimated effect in the
anticipated direction, but only the mean MDASI interference had a p value ≤ 0.05 for its
marginal effect when added to the base model.
Further investigation found that the effect of mean MDASI interference depended on ECOG
PS, so the model with this interaction was also considered (Table 2). When the interaction
was included, the effect of mean MDASI interference on overall survival was significant
only among patients with poor ECOG PS. The estimate and 95% Wald confidence interval
for the adjusted HR of a one-point increase in mean MDASI interference was 1.03 (0.89–
1.20) for the good ECOG PS group and 1.58 (1.26–1.99) for the poor ECOG PS group.
Figure 2 depicts these estimates and 95% confidence intervals for the stratum-specific
adjusted HRs.
Because the multivariate Cox proportional hazards models were stratified by ECOG PS, the
C statistic was computed within each stratum and by combining the stratum-specific
concordance results (Table 2). The overall C statistic for all models was low, but when
computed separately within each stratum, the C statistics revealed that for each model the
concordance was substantially higher among patients with poor ECOG PS than among those
with good ECOG PS.
The bootstrap procedures yielded results agreeing with the earlier findings. The 95%
bootstrap confidence intervals for each PRO’s adjusted HR are shown in Table 3. Not
surprisingly, these intervals tended to be wider than Wald-based confidence intervals [25,
30]. Mean MDASI interference was the only PRO for which the confidence interval
excluded 1.00, and when allowed to be stratum specific, symptom interference had a marked
effect for the poor ECOG PS stratum but not for the good ECOG PS stratum.
The proportions of bootstrap resamples in which each PRO had p ≤ 0.05 when added to the
base model are given in Table 4. These proportions were high only for the mean MDASI
interference score.
Discussion
Our results indicate that symptom interference may be a prognostic factor for overall
survival in patients with stage IV NSCLC. This finding seemed robust despite the small
sample size. Some of the evidence for the added prognostic benefit of the mean MDASI
symptom interference score might be attributable to the increased precision that this PRO
offers compared with ECOG PS, which is already categorical and which we further
dichotomized. Still more of the evidence might be due to the restricted range of ECOG PS in
the analysis data set: no patients had baseline ECOG PS = 4 and only 3% had ECOG PS = 3.
Even so, a particular range of ECOG PS scores might be expected for patients who are
eligible for a particular treatment. Therefore, a PRO might further differentiate patients
likely to live longer from those likely to live shorter, at least if the patients have poor
performance status.
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Guidelines for the interpretation of C statistics [31] indicate that the models considered in
this analysis may not be comparable to those used in clinical practice. One possible cause of
the relatively poor prognostic ability of all models considered is that the patient population
was limited to patients with stage IV NSCLC, who would be expected to die sooner than
patients with early-stage NSCLC. Therefore, stage, which has previously been identified as
a significant prognostic factor for overall survival in patients with NSCLC [32], could not be
used to improve the model.
Of the many available patient-reported measures, we considered only a few for our
retrospective analyses. Ideally, more PRO instruments would have been considered.
Availability of data from the EORTC QLQ-C30 [6], for instance, would have permitted us
to consider the physical functioning scale, which Braun et al. reported as a prognostic factor
for NSCLC [32]. The ability to verify the usefulness of EORTC’s physical functioning scale
would have been especially useful in our assessment of the added prognostic benefit of
PROs after adjustment for ECOG PS, because Braun et al. did not control for performance
status. Likewise, although we included one single-item measure (SF-12 general health), it
was not the same single-item measure (overall quality of life) previously shown to be a
significant prognostic factor in NSCLC [11].
Most of the PROs we considered did not meet our criterion for having a significant added
benefit, but this might be because our analysis data set was relatively small, especially if one
considers the ratio of observed deaths to prognostic factors. Even most of the demographic
and clinical factors were generally not significant. For example, sex was the non-PRO factor
that had the strongest evidence for being important, but it was not statistically significant in
many of our models even though it was demonstrated to be a significant prognostic factor in
a larger data set [33]. In addition, all of the patients in this study were treated at a tertiary
cancer center; however, Cleeland et al. [20] showed that type of treatment site is associated
with differences in symptom management. Further studies should include patients from
different patient populations and treatment settings, including community clinics and public
hospitals, and should include more PROs.
We do not claim that symptom interference is the best PRO for use as a prognostic factor in
oncology research and practice. Instead, we note that it demonstrated a statistically
significant effect in a prognostic model in advanced lung cancer despite a small sample size
and despite adjustments for multiple clinical and demographic factors. It is especially
interesting that symptom interference—a patient-reported measure that has not been
extensively studied as a prognostic factor—was more predictive in our analysis than
demographic or clinical factors and was not redundant in models stratified by ECOG PS. In
fact, the usefulness of the measure seemed to entirely depend on ECOG PS, suggesting that
symptom interference and clinician-assessed performance status should be seen as
complementary. To our knowledge, the interactive effect of symptom interference and
performance status as a prognostic factor for overall survival in NSCLC has not been
previously established. While our results apply directly to patients with advanced NSCLC, it
is plausible that mean MDASI symptom interference and/or other PROs could serve as
important prognostic factors in other patient populations, especially for patients with
advanced disease. Hence, the use of the MDASI symptom interference is encouraged to
assist in providing clinicians with prognostic information in practice.
Some have proposed using PROs as stratifying factors in clinical trials because of their
frequent superiority vis-à-vis performance status in predicting survival [34]. We agree that
PROs should be considered in randomization strata. Our findings also suggest that the utility
of at least one PRO as a prognostic factor depends on performance status. Further attention
should be devoted to studying possible interaction effects between performance status and
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PROs, especially symptom interference, in prognostic models. In addition, future studies
should include patients across all types and stages of cancer.
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Fig. 1.
Estimated overall survival curves for two “average” patients with stage IV NSCLC who
differ at baseline only by ECOG PS group membership
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Fig. 2.
Estimates and 95% confidence intervals of the adjusted HR associated with a one-point
increase in mean MDASI symptom interference level, by ECOG PS stratum; HR > 1
indicates difference in survival
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Table 4
Proportion of bootstrap resamples for which the PRO measure was a significant prognostic factor for overall
survival when added to the base model containing only demographic and clinical factors
PRO measure Proportion of bootstrap resamples with effect
having p ≤ 0.05
Mean MDASI interference (no interaction considered) 0.769
Mean MDASI symptom severity 0.229
SF-12 PCS 0.294
SF-12 MCS 0.093
SF-12 general health 0.200
Mean MDASI interference (interacting with ECOG PS)
  Main Interference effect Additional Interference effect 0.075
  (if ECOG PS ≥ 2) 0.870
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